[Research progress in the adjunct therapy of recurrent respiratory papillomatosis]

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Dec;34(12):1145-1148. doi: 10.13201/j.issn.2096-7993.2020.12.022.
[Article in Chinese]

Abstract

Recurrent respiratory papillomatosis (RRP) is a benign tumor of the respiratory tract caused by human papillomavirus (HPV) infection. At present, there is no cure for this disease, and mainly depends on surgical resection to relieve symptoms but cannot prevent recurrence. Multiple surgeries will bring heavy mental and economic burdens to patients and their families. Therefore, researchers are constantly seeking new treatments to reduce the number of operations and prevent recurrence. Hence, research on adjuvant therapy drugs has also been widely carried out, including bevacizumab, cidofovir, HPV vaccine, and Chinese medicine as an adjuvant drug according some reports. This article reviews the adjuvant treatment of RRP in recent years.

Keywords: adjunct therapy; drug therapy; papilloma; respiratory tract diseases.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic
  • Combined Modality Therapy
  • Humans
  • Papillomavirus Infections* / therapy
  • Papillomavirus Vaccines*
  • Respiratory Tract Infections*

Substances

  • Adjuvants, Immunologic
  • Papillomavirus Vaccines

Supplementary concepts

  • Recurrent respiratory papillomatosis

Grants and funding

北京市自然基金(No:7182036)和北京市医院管理中心儿科学科协同发展中心专项经费(No:XTCX201823)联合资助